EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR

被引：0

作者：

Branford, S. ^{[1
]}

Kamel-Reid, S. ^{[2
]}

Bendit, I. ^{[3
]}

Etienne, G. ^{[4
]}

Guerci-Bresler, A. ^{[5
]}

Hughes, T. P. ^{[6
]}

Lipton, J. H. ^{[7
]}

Leber, B. ^{[8
]}

Spector, N. ^{[9
]}

Steegmann, J. L. ^{[10
]}

Acharya, S. ^{[11
]}

Collins, L. ^{[12
]}

Dalal, D. ^{[12
]}

Cervantes, F. ^{[13
]}

机构：

[1] Univ Adelaide, Ctr Canc Biol, SA Pathol, Adelaide, SA 5005, Australia

[2] Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M4X 1K9, Canada

[3] Univ Sao Paulo Med Sch, Sao Paulo, Brazil

[4] Inst Bergonie, Bordeaux, France

[5] Hop Brabois, CHU Nancy, Vandoeuvre Les Nancy, France

[6] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[8] McMaster Univ, Juravinski Hosp & Canc Ctr, Hamilton, ON, Canada

[9] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil

[10] Hosp Univ Princesa, Madrid, Spain

[11] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India

[12] Novartis Pharmaceut, E Hanover, NJ USA

[13] Univ Barcelona, IDIBAPS, Hosp Clin, Barcelona, Spain

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S1361

引用

页码：532 / 532

页数：1